Effects of antidiabetic drugs on bone metabolism.
Nuria Padilla ApuntateCarmen G Puerto CabezaAlba Gallego-RoyoNuria Goñi RosClaudia Abadía MolinaJavier Acha PérezPilar CalmarzaPublished in: Advances in laboratory medicine (2024)
Bone remodeling is influenced by the type of antidiabetic drug administered to DMT2 patients. In our study, the patients who received pioglitazone showed higher β-CTx concentrations, as compared to patients treated with other types of antidiabetic drugs. This finding highlights the convenience of avoiding these drugs, especially in postmenopausal women with DMT2. GLP1ra drugs were associated with the lowest β-CTx concentrations, which suggests that these agents could exert beneficial effects on bone metabolism.
Keyphrases
- bone mineral density
- end stage renal disease
- soft tissue
- ejection fraction
- postmenopausal women
- newly diagnosed
- drug induced
- chronic kidney disease
- rheumatoid arthritis
- bone loss
- bone regeneration
- peritoneal dialysis
- prognostic factors
- escherichia coli
- systemic lupus erythematosus
- ankylosing spondylitis
- disease activity
- adverse drug
- patient reported